
Aragen Life Sciences has started operations at Aragen OneHP, an integrated high-potency development and manufacturing platform at its Nacharam campus in Hyderabad, the company announced on 7 October. The 15,000-square-foot facility has one manufacturing line with a designed capacity of 500 to 600 kg of active pharmaceutical ingredients annually and can handle highly potent compounds including cytotoxic molecules used in oncology. The platform is designed for occupational exposure limits of up to 10 ng/m³ and will support future expansion into antibody-drug conjugates and peptide-drug conjugates.
Aragen has invested over Rs 1,000 crore in capital expenditure over the three years to March 2026. Its contract development and manufacturing segment registered a 19% compound annual growth rate during this period, with installed small-molecule capacity reaching 364 KL across Hyderabad and Visakhapatnam. The company, which filed for an IPO in August 2026, employs 4,362 people and served 591 global customers in FY26, including 16 of the world’s top 20 pharmaceutical companies.
Update, 8 October 2026: Medical Dialogues now also reports the launch, adding that Aragen's Hyderabad facilities are accredited by the USFDA, EDQM, PMDA, MFDS, ANVISA, WHO Geneva and CDSCO. The outlet confirms the investment, capacity and IPO details previously reported by other sources.
All four sources report the same launch of Aragen's high-potency platform in Hyderabad with near-identical factual details: size, capacity, investment and growth rates. The timesofindia adds the former company name (GVK BIO) and FY26 customer data, 591 global clients including 16 of the top 20 pharma firms, which the others omit. medicaldialogues.in alone lists the facilities' international regulatory accreditations. The Hindu includes the most complete IPO detail: an Rs 800 crore fresh issue and an offer for sale of 27.3 million shares. The Economic Times and The Hindu both quote CEO Aniel Khubchandani on integrated development. No source adopts a critical or political framing, coverage is uniformly promotional in tone, focused on capability expansion. The next concrete item is the IPO, which Aragen filed for in August 2026 and which awaits SEBI approval.
Coverage: 4 sources, 4 neutral
Sources (4): economictimes.indiatimes.com (neutral report), thehindu.com (neutral report), timesofindia.indiatimes.com (neutral report), medicaldialogues.in (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Methodology and corrections.